BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND TOP1, RP3-511B24_2, 7150, ENSG00000198900, TOPI, P11387 AND Prognosis
11073 results:

  • 1. Prognostic Implications of Small Cell lung cancer Transcriptional Subtyping for CNS Metastases.
    Tringale KR; Skakodub A; Egger J; Eichholz J; Yu Y; Gomez D; Rimner A; Li B; Yamada Y; Wilcox J; Moss N; Imber BS; Rekhtman N; Baine MK; Rudin CM; Pike LRG
    JCO Precis Oncol; 2024 Apr; 8():e2300470. PubMed ID: 38691815
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A retrospective clinical analysis of 11 cases of PEComa from different sites.
    Yan J; Zhou D; Wang Y; Yang B; Wang Y; Zhang K; Zhang S; Zhang B; Meng Q; Lv Q
    World J Surg Oncol; 2024 Apr; 22(1):116. PubMed ID: 38689335
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Targeting KRAS in pancreatic cancer.
    Stickler S; Rath B; Hamilton G
    Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Transitioning to a Personalized Approach in Molecularly Subtyped Small-Cell lung cancer (SCLC).
    Grenda A; Krawczyk P; Obara A; Gajek Ł; Łomża-Łaba A; Milanowski J
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673793
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Smoking, lung cancer Stage, and Prognostic Factors-Findings from the National lung Screening Trial.
    Zhu J; Branstetter S; Lazarus P; Muscat JE
    Int J Environ Res Public Health; 2024 Mar; 21(4):. PubMed ID: 38673313
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The impact of COVID-19 on the prognosis of deep vein thrombosis following anticoagulation treatment: a two-year single-center retrospective cohort study.
    Wang Q; Wu J; Zhang P; Ma X
    BMC Pulm Med; 2024 Apr; 24(1):208. PubMed ID: 38671424
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Limited resection is comparable to lobectomy for tumor size ≤ 2 cm pulmonary invasive mucinous adenocarcinoma.
    Lin W; Su H; Xie H; Xu L; Wang T; Wang L; Hu X; Zhao D; Zhu Y; Wang H; Jiang G; Xie D; Chen C;
    World J Surg Oncol; 2024 Apr; 22(1):109. PubMed ID: 38664816
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review.
    Guo Y; Pan Y; Wan J; Gong B; Li Y; Kan X; Zheng C
    BMC Cancer; 2024 Apr; 24(1):523. PubMed ID: 38664760
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. High core 1β1,3-galactosyltransferase 1 expression is associated with poor prognosis and promotes cellular radioresistance in lung adenocarcinoma.
    Chen Y; Ji Y; Shen L; Li Y; Ren Y; Shi H; Li Y; Wu Y
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):214. PubMed ID: 38662050
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Evaluation of the preoperative neutrophil-to-lymphocyte ratio as a predictor of the micropapillary component of stage IA lung adenocarcinoma.
    Chen C; Chen ZJ; Li WJ; Deng T; Le HB; Zhang YK; Zhang BJ
    J Int Med Res; 2024 Apr; 52(4):3000605241245016. PubMed ID: 38661098
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
    Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
    Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses.
    Xu K; Lu W; Yu A; Wu H; He J
    BMC Cancer; 2024 Apr; 24(1):491. PubMed ID: 38632512
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors.
    Nishimura T; Fujimoto H; Fujiwara T; Ito K; Fujiwara A; Yuda H; Itani H; Naito M; Kodama S; Furuhashi K; Yagi A; Saiki H; Yasuma T; Okano T; Tomaru A; Tanigawa M; Yoshida M; Hataji O; Ibata H; D'Alessandro-Gabazza CN; Gabazza EC; Kobayashi T
    Cancer Med; 2024 Apr; 13(8):e7188. PubMed ID: 38629295
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Pamiparib as consolidation treatment after concurrent chemoradiotherapy of limited-stage small cell lung cancer: a single-arm, open-label phase 2 trial.
    Mao J; Ni J; Chu L; Chu X; Xu D; Yang X; Zhu Z
    Radiat Oncol; 2024 Apr; 19(1):47. PubMed ID: 38610031
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients.
    Xu Y; Zhang Q; Chen Z; Yang S; Chen H; Xiao X; Jiang H
    BMC Pulm Med; 2024 Apr; 24(1):174. PubMed ID: 38609918
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Targeted therapeutic options in early and metastatic NSCLC-overview.
    Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
    Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. ESCO2's oncogenic role in human tumors: a pan-cancer analysis and experimental validation.
    Huang Y; Chen D; Bai Y; Zhang Y; Zheng Z; Fu Q; Yi B; Jiang Y; Zhang Z; Zhu J
    BMC Cancer; 2024 Apr; 24(1):452. PubMed ID: 38605349
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Computational identification and experimental verification of a novel signature based on SARS-CoV-2-related genes for predicting prognosis, immune microenvironment and therapeutic strategies in lung adenocarcinoma patients.
    Wang Y; Xu Y; Deng Y; Yang L; Wang D; Yang Z; Zhang Y
    Front Immunol; 2024; 15():1366928. PubMed ID: 38601163
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data.
    Hong S; Lee JH; Heo JY; Suh KJ; Kim SH; Kim YJ; Kim JH
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):186. PubMed ID: 38600328
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. [Clinical characteristics and prognosis analysis of 17 cases of SMARCA4-deficient chest tumors].
    Cao XN; Li Z; Wang QY
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):325-331. PubMed ID: 38599807
    [No Abstract]    [Full Text] [Related]  


    [Next]

    of 554.